American Century Companies’s Neurogene NGNE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$734K Buy
23,330
+4,790
+26% +$132K ﹤0.01% 2494
2026
Q1
$374K Buy
18,540
+980
+6% +$19K ﹤0.01% 2591
2025
Q4
$362K Buy
17,560
+3,929
+29% +$97.8K ﹤0.01% 2593
2025
Q3
$236K Buy
+13,631
New +$274K ﹤0.01% 2672
2024
Q2
Sell
-6,747
Closed -$343K 2918
2024
Q1
$343K Buy
+6,747
New +$225K ﹤0.01% 2585

Other funds holding NGNE

American Century Companies's NGNE Position: Q2 2026 in Review

American Century Companies increased its Neurogene (NGNE) stake by 26% in Q2 2026, buying an estimated $132K and bringing the position to 23,330 shares worth $734K. The position accounts for ﹤0.01% of the portfolio, ranked #2494.

American Century Companies first reported a position in NGNE in Q1 2024 and has held it in 5 quarters since. 102 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • American Century Companies held 23,330 shares of Neurogene worth $734K as of Q2 2026.
  • American Century Companies bought 4,790 Neurogene shares in Q2 2026, an estimated $132K.
  • Neurogene made up ﹤0.01% of American Century Companies's portfolio in Q2 2026, its #2494 holding.
  • American Century Companies first reported a position in Neurogene in Q1 2024 and has held it in 5 quarters since.
  • 102 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.